- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00438971
The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder
Study Overview
Detailed Description
Panic Disorder is relatively common, with a lifetime prevalence of 3.5 % (Kessler, et al 1994) and characterized by a typically chronic course (Marzol & Pollack, 2000). Affected individuals tend to be high utilizers of general health care services, frequently receiving extensive and unrevealing medical work-ups (Katon, 1997); while the panic disorder itself often goes unrecognized (Sartorious, et al 1993). Panic disorder has a significant negative impact on work, family, and social life (Rubin, et al 2000), and is associated with increased rates of negative life events and diminished overall quality of life (Cramer, et al 2005). Research indicates that the quality of life and well-being of patients with panic disorder is similarly or more impaired than that of patients with serious medical illnesses, such as type II diabetes (Rubin, et al 2000).
Treatment of panic disorder is focused on the reduction of panic attacks, avoidance behavior, and anticipatory anxiety, as well as the resolution of comorbid conditions. The overarching goal of panic disorder treatment is reduction in symptoms to allow improvement in overall quality of life (Pollack, 2005).
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that has greater initial noradrenergic effects than venlafaxine (Goldstein, et al 2004). Recent data from a placebo controlled fixed dose study, suggested that venlafaxine at 225 mg/d (a dose at which noradrenergic effects are likely to be relevant), was more efficacious on a number of measures of panic disorder than the SSRI, paroxetine (Pollack, et al 2003). This data, combined with our clinical experience with duloxetine to date, support the assertion that duloxetine is likely to prove an effective agent for panic disorder.
Thus, we propose to perform the first systematic examination of the efficacy of duloxetine for panic disorder in a study in which 15 patients with panic disorder will receive duloxetine flexibly dosed from 30 to 120 mg/d in open treatment for 8 weeks. Information learned in this study will help guide treatment selection for panic disorder by providing initial open efficacy data for duloxetine in panic disorder.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- The Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female outpatients, age 18-75.
- Diagnosis of Panic Disorder with or without Agoraphobia by DSM-IV criteria
- MGH Panic Clinical Global Impression of Severity score Score equal to or greater than 4
- Patients with current major depressive disorder will be allowed if the panic disorder is primary (as determined on interview by clinician and patient), and the baseline MADRS score is less than or equal to 20
- Willingness and ability to comply with the requirements of the study protocol.
Exclusion Criteria:
- Pregnant or lactating women or others not using acceptable means of birth control (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, implanted progesterone rods stabilized for at least 3 months).
- Patients with current or history of posttraumatic stress disorder, obsessive compulsive disorder, bipolar disorder, schizophrenia or other psychotic conditions.
- Patients on other psychoactive medication, including MAOIs, and those with the potential need to use an MAOI during the study or within 5 day of discontinuation of study drug will be excluded. Participants must have discontinued MAOI use at least 14 days prior study baseline. Patients must discontinue regular benzodiazepine or other non-MAOI antidepressant therapy at least one week (5 weeks for fluoxetine) prior to baseline. Concomitant beta-blockers are proscribed unless prescribed for a medical indication (e.g., hypertension, at a stable daily dose for > 1 month).
- Patients with a history of alcohol or substance abuse or dependence within the last twelve months, significant alcohol dependence, or a positive toxicology screen consistent with abuse at baseline.
- Patients with significant or unstable neurological or medical disorders or instability for which hospitalization may be likely within the next year. In particular, patients with end-stage renal disease (requiring dialysis) or severe renal impairment, or hepatic insufficiency (defined as twice normal on LFTs as follows: SGPT >110 u/L or SGOT >80 u/L) will be excluded.
- Patients with uncontrolled narrow-angle glaucoma will be excluded.
- Seizure disorders with the exception of a history of febrile seizures if they occurred during childhood, were isolated, and did not recur in adulthood.
- Severe personality disorders likely to interfere with study participation.
- Ongoing psychotherapy directed toward the treatment of the panic disorder or agoraphobia. Prohibited psychotherapy includes cognitive behavioral therapy or psychodynamic therapy that focuses on exploring specific, dynamic causes of the panic or phobic symptoms and provides skills for their management, or any of the active ingredients of these psychotherapies. General supportive individual, couples, or family therapy greater than 2 months duration is acceptable.
- History of hypersensitivity or prior non-response or intolerance of duloxetine.
- Patients who have failed 4 or more medication trials of at least 4 weeks at adequate dose (e.g. paroxetine 20mg or equivalent). Treatment failure is here defined as clinician judgment based on assessment of patient history of prior treatment of minimal or no reduction in panic attacks, anticipatory anxiety or avoidance during a specific, medication trial.
- Patients with significant suicidal ideation (MADRS item 10 score > 3) or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Duloxetine
|
Treatment will be initiated at 30mg/day in the first week (week 0), and then increased to 60mg/day at week 1, with the option to increase to 90mg at week 4, and 120mg at week 6.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Panic Disorder Severity Scale (PDSS)
Time Frame: 8 weeks
|
The PDSS contains seven items assessing multiple dimensions of panic disorder severity, including (a) frequency of panic attacks, (b) distress during panic attacks, (c) anticipatory anxiety, (d) agoraphobic fear and avoidance, (e) interoceptive fear and avoidance, (f) impairment of work functioning, and (g) impairment of social functioning.
The PDSS ranges from 0 to 28, with higher ratings reflecting greater degrees of symptom severity.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Global Impression of Severity Scale (CGI-S)
Time Frame: 8 weeks
|
The CGI-S is a clinician-rated instrument used to assess global severity of symptoms.
The CGI-S ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill).
Remission was defined strictly as a CGI-S score of 1 or 2 (not at all ill or borderline ill) and zero panic attacks at endpoint.
|
8 weeks
|
Panic Attack Scale (PAS)
Time Frame: 8 weeks
|
The PAS is a measure that assesses participants' total number of panic attacks (situational and unexpected with full and limited symptoms), as well as anticipatory anxiety, since last visit.
There is no total score.
|
8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Montgomery Asberg Depression Rating Scale (MADRS)
Time Frame: 8 weeks
|
The MADRS is a 10-item clinician rating of depressive symptoms.
Scores range from 0 to 60, with higher scores reflecting greater symptom severity.
|
8 weeks
|
Beck Anxiety Inventory (BAI)
Time Frame: 8 weeks
|
The BAI is a 21-item self-report measure of anxiety with a focus on somatic symptoms.
Total scores range from 0 to 63, with higher scores reflecting greater symptom severity.
|
8 weeks
|
Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)
Time Frame: 8 weeks
|
The Q-LES-Q is a self-report measure of the degree of enjoyment and satisfaction experienced by subjects in various areas of daily functioning.
Only the first 14 items are included in scoring, which ranges from 14 to 70, with higher scores reflecting greater enjoyment and satisfaction.
The last two items are not included in the total score but are standalone items.
|
8 weeks
|
Sheehan Disability Scale (SDS)
Time Frame: 8 weeks
|
The SDS is a 3-item measure with each item rated on a 10-point scale.
The SDS measures the extent to which work/school, social life, and home life or family responsibilities are impaired by symptoms.
Total scores range from 0 to 30, with higher scores reflecting greater impairment.
|
8 weeks
|
Longitudinal Interval Follow-up Evaluation Range of Impaired Functioning Tool (LIFE-RIFT)
Time Frame: 8 weeks
|
The LIFE-RIFT is a brief measure of psychosocial functioning in work, interpersonal relations, satisfaction, and recreation.
Scores on the LIFE-RIFT can range from 4, indicating very good functioning (no impairment) in all of the 4 component areas, to 20, indicating very poor functioning (severe impairment) in all of the 4 areas.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mark H Pollack, M.D., Massachusetts General Hospital
Publications and helpful links
General Publications
- Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994 Jan;51(1):8-19. doi: 10.1001/archpsyc.1994.03950010008002.
- Marzol PC, Pollack MH. New developments in panic disorder. Curr Psychiatry Rep. 2000 Aug;2(4):353-7. doi: 10.1007/s11920-000-0081-8.
- Katon W, Hart R, Montano B. The effect of panic disorder in the managed care setting. Manag Care Interface. 1997 Nov;10(11):88-94, 98.
- Sartorius N, Ustun TB, Costa e Silva JA, Goldberg D, Lecrubier Y, Ormel J, Von Korff M, Wittchen HU. An international study of psychological problems in primary care. Preliminary report from the World Health Organization Collaborative Project on 'Psychological Problems in General Health Care'. Arch Gen Psychiatry. 1993 Oct;50(10):819-24. doi: 10.1001/archpsyc.1993.01820220075008.
- Rubin HC, Rapaport MH, Levine B, Gladsjo JK, Rabin A, Auerbach M, Judd LL, Kaplan R. Quality of well being in panic disorder: the assessment of psychiatric and general disability. J Affect Disord. 2000 Jan-Mar;57(1-3):217-21. doi: 10.1016/s0165-0327(99)00030-0.
- Cramer V, Torgersen S, Kringlen E. Quality of life and anxiety disorders: a population study. J Nerv Ment Dis. 2005 Mar;193(3):196-202. doi: 10.1097/01.nmd.0000154836.22687.13.
- Pollack MH. The pharmacotherapy of panic disorder. J Clin Psychiatry. 2005;66 Suppl 4:23-7.
- Pollack MH, Meoni P, Otto MW, Simon N, Hackett D. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol. 2003 Jun;23(3):250-9. doi: 10.1097/01.jcp.0000084025.22282.84. Erratum In: J Clin Psychopharmacol. 2004 Feb;24(1):112.
- Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004 Aug;24(4):389-99. doi: 10.1097/01.jcp.0000132448.65972.d9.
- Simon NM, Kaufman RE, Hoge EA, Worthington JJ, Herlands NN, Owens ME, Pollack MH. Open-label support for duloxetine for the treatment of panic disorder. CNS Neurosci Ther. 2009 Winter;15(1):19-23. doi: 10.1111/j.1755-5949.2008.00076.x.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Anxiety Disorders
- Disease
- Panic Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Duloxetine Hydrochloride
Other Study ID Numbers
- 2006-P-000263
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Panic Disorder
-
Philipps University Marburg Medical CenterGerman Federal Ministry of Education and ResearchCompletedPanic Disorder With Agoraphobia | Panic Disorder Without AgoraphobiaGermany
-
Beth Israel Medical CenterTerminatedPanic Disorder | Major Depressive Disorder With Panic AttacksUnited States
-
Ulrike WillutzkiUnknownDepression | Panic Disorder | Agoraphobia | Panic Disorder With Agoraphobia | Agoraphobia With Panic AttacksGermany
-
Charite University, Berlin, GermanyRecruitingGeneralized Anxiety Disorder | Social Anxiety Disorder | Panic Disorder With Agoraphobia | Panic Disorder Without AgoraphobiaGermany
-
Beth Israel Medical CenterCompletedPanic Disorder | Major Depression With Panic AttacksUnited States
-
Southern Methodist UniversityBoston University; University of MichiganCompletedPanic Disorder With AgoraphobiaUnited States
-
Karolinska InstitutetCompleted
-
Region SkaneCompletedPanic Disorder (With or Without Agoraphobia)Sweden
-
Michael E. DeBakey VA Medical CenterSouth Central VA Mental Illness Research, Education & Clinical CenterUnknown
-
Ruhr University of BochumTerminatedPanic Disorder With AgoraphobiaGermany
Clinical Trials on Duloxetine
-
Shanghai Mental Health CenterJiangsu Nhwa Pharmaceutical Co., Ltd.Completed
-
Boehringer IngelheimCompletedDiabetic Neuropathies | Depressive Disorder, MajorGermany
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.RecruitingMajor Depressive Disorder (MDD)China
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Completed
-
University of MinnesotaHoffmann-La Roche; Minnesota Medical FoundationCompleted
-
University of PittsburghEli Lilly and Company; National Institutes of Health (NIH)CompletedBack Pain | Major Depressive Disorder | AgedUnited States
-
Hamilton Health Sciences CorporationSt. Joseph's Healthcare Hamilton; Eli Lilly and Company; McMaster UniversityUnknown
-
New York State Psychiatric InstituteEli Lilly and CompanyCompletedDysthymic Disorder | Depressive Disorder NOSUnited States
-
Eli Lilly and CompanyShionogiCompleted
-
Boehringer IngelheimCompleted